Free Newsletter
Astellas to shrink Oklahoma payroll
The so-called "patent cliff" isn't just hurting the biggest pharma companies--or pushing them to downsize. Tokyo-based Astellas Pharma, facing the expiration of its Flomax drug patent, is offering early retirement and "voluntary termination" to its 200-strong workforce in Norman, Oklahoma. That's where Flomax is produced, and the company expects volume at that plant to fall so sharply that it won't need nearly as many workers.
The program is aimed at cutting the Norman payroll by about 30 percent, or 60 workers. Other products made there include VESIcare, a bladder-control medication, and another product solely for the Japanese market, Gaster D.
- read the story in The Oklahoman
Related Articles:
Astellas faces new delay for Advagraf approval
The 2008 patent retreat
Blockbusters on their way to generic-land
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: